Member Info for Laura2022

It was clear they're be more skeletons

I did suspect more skeletons as I stated weeks before suspension

Following the independent review first announced by John Wood Group PLC ("Wood" or the "Company") on 7 November 2024, the Company has been notified by the Financial Conduct Authority (the "FCA") of its commencement of an investigation into the Company covering the period from 1 January 2023 to 7 November 2024.

The Company will cooperate fully with the FCA in relation to this investigation.

Up nearly 100% up..

Think VAST will do similar

Also getting slightly more expensive

Be great if PYC finishes above 0.5

These large buys happening this last 2 days now

Think VAST breaks out before close

Chart breakout is today /Monday

0.4p breaks up to 0.5

Guuvi

Thanks for that

That's very big

Nearly 20% up on the buys from 26/26 5

36-37 with not much stock at 37

I am in agreement Trench123

Very interesting developments at Beyond Blood, which itself is valued at over £15mln

Rider

I believe its a similar model to Burford but I might be wrong

Posting at 4.30am on a share you dont hold, yet you've gone silent on SCE which loses £10mln year and isn't a going concern

Very strange

20 days to build up to that

Great 1st post John

Filtered

Macd chsrt breakout also

After weeks of consolidation

Target from 0 37p now placing done is 0.8p+

BTC stocks is now collapsed , money to move into core AIM market now

These strange accounts just keep popping up

This person has an account for a few weeks, mostly on LLOYD then just pops up on PYC

Another for the ignore and filter list

As you say Burt, CEO on £72k is one of lowest on AIM so not quite sure of the 'lifestyle " claim

1d

Smarter decisions lead to faster drug development. 🧪

With the FDA’s shift away from Maximum Tolerated Dose (MTD) in cancer treatments and the phasing out of mandatory animal testing, the drug development landscape is rapidly evolving. In this dynamic environment, data-driven decisions are essential for navigating complexity, ensuring regulatory compliance, and optimising the path to clinical success.

With over two decades of expertise, our team integrates Model-Informed Drug Development (MIDD), data science, and biostatistics to deliver insights that empower smarter decision-making throughout the drug development process. From preclinical to clinical development, we help our partners streamline drug development, reduce risks, and bring effective treatments to market faster.

As regulatory requirements evolve and the demand for precision medicine grows, MIDD is becoming an indispensable tool for achieving clinical success.

The net cash raised from the Fundraise will be used for the primary beneficiation of the diamond parcels, which is expected to significantly enhance their value; providing financial support for the Company’s new technical team to commence working on the current projects accelerate implementation of the comprehensive technical review announced on 12 June 2025;

Paulie

Hello

Probably as the recent placing at 0.35p means some brokers and people will simply take their easy10%

VAST will be alot higher next week